Psoriasis: key endpoint results by drug
The key endpoints of Psoriasis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Psoriasis page.
PASI 75 (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 77.8% | 11.5% | +66.3 | Eow · wk 12 · n 338 | NCT01646073 Phase 3, primary |
| apremilast | 33.1% | 5.3% | +27.8 | wk 16 · n 562 | NCT01194219 Phase 3, primary |
| baricitinib | 54.1% | 16.7% | +37.4 | 10 mg · wk 12 · n 61 | NCT01490632 Phase 2, primary |
| bimekizumab | 76.9% | 2.4% | +74.5 | 320 mg Q4W · wk 4 · n 321 | NCT03370133 Phase 3, secondary |
| brepocitinib | 60% | 13% | +47 | 60 mg Once Daily (QD) Followed by 30 mg QD · wk 12 · n 25 | NCT02969018 Phase 2, secondary |
| Calcipotriene/Betamethasone Dipropionate Foam | 50% | 14.3% | +35.7 | wk 16 · n 14 | NCT03441789 Phase 4, primary |
| certolizumab pegol | 66.7% | 5% | +61.7 | 400 mg Q2W · wk 12 · n 167 | NCT02346240 Phase 3, primary |
| deucravacitinib | 53% | 9.4% | +43.6 | wk 16 · n 511 | NCT03611751 Phase 3, primary |
| Envudeucitinib | 56.4% | 0% | +56.4 | 40mg QD · wk 12 · n 39 | NCT05600036 Phase 2, primary |
| etanercept | 57% | 11% | +46 | wk 12 · n 106 | NCT00078819 Phase 3, primary |
| Girocitinib | 35.5% | 21.4% | +14.1 | wk 12 · n 31 | NCT05772520 Phase 2, primary |
| guselkumab | 84.1% | 6.3% | +77.8 | 100 mg · wk 16 · n 63 | NCT02325219 Phase 3, secondary |
| icotrokinra | 65.1% | 9.3% | +55.8 | 100 mg QD · wk 16 · n 43 | NCT05223868 Phase 2, primary |
| infliximab | 81% | 2.2% | +78.8 | wk 10 · n 84 | NCT01177800 Phase 3, primary |
| ixekizumab | 84.2% | 7.3% | +76.9 | 80 mg every 4 weeks · wk 12 · n 386 | NCT01646177 Phase 3, primary |
| mirikizumab | 82.5% | 9.3% | +73.2 | 250 mg Q4W · wk 16 · n 423 | NCT03482011 Phase 3, secondary |
| netakimab | 77.6% | 0% | +77.6 | Q2W · wk 12 · n 85 | NCT03390101 Phase 3, primary |
| Piclidenoson | 8.5% | 6.9% | +1.6 | 2 mg · wk 12 · n 141 | NCT01265667 Phase 2/3, primary |
| risankizumab | 85.2% | 85.7% (Ustekinumab) | — | wk 16 · n 54 | NCT04435600 Phase 3, primary |
| Roflumilast (Zoryve) | 41.6% | 7.6% | +34 | 0.3% cream · wk 8 · n 255 | NCT04211363 Phase 3, secondary |
| secukinumab | 77.1% | 4.9% | +72.2 | 300mg · wk 12 · n 323 | NCT01358578 Phase 3, primary |
| sonelokimab | 84.9% | 90.6% (Secukinumab) | — | 120 mg · wk 12 · n 53 | NCT03384745 Phase 2, secondary |
| Tapinarof | 36.1% | 10.2% | +25.9 | wk 12 · n 340 | NCT03956355 Phase 3, secondary |
| tildrakizumab | 66.3% | 4.4% | +61.9 | 100 mg · wk 16 · n 89 | NCT01225731 Phase 2, primary |
| tofacitinib | 63.6% | 5.6% | +58 | 10 mg BID · wk 12 · n 330 | NCT01241591 Phase 3, primary |
| ustekinumab | 75.7% | 3.7% | +72 | 90 mg · wk 12 · n 411 | NCT00307437 Phase 3, primary |
| Voclosporin | 13.3% | 3.5% | +9.8 | 0.2 · wk 12 · n 105 | NCT00244842 Phase 3, primary |
| zasocitinib | 67.3% | 5.8% | +61.5 | 30 mg · wk 12 · n 52 | NCT04999839 Phase 2, primary |
Drugs checked with no result here: 19 not posted, 36 not reported, 14 trial running.
PASI 90 (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 61.8% | 54.2% (EU RPP) | — | wk 16 · n 267 | NCT02581345 Phase 3, secondary |
| apremilast | 55.9% | 5.1% (APR) | — | wk 16 · n 118 | NCT04908475 Phase 4, primary |
| bimekizumab | 85% | 4.8% | +80.2 | 320 mg Q4W · wk 16 · n 321 | NCT03370133 Phase 3, primary |
| brepocitinib | 20% | 4.3% | +15.7 | 60 mg Once Daily (QD) Followed by 30 mg QD · wk 16 · n 25 | NCT02969018 Phase 2, secondary |
| certolizumab pegol | 55.4% | 4.5% | +50.9 | 400 mg Q2W · wk 16 · n 87 | NCT02326272 Phase 3, secondary |
| deucravacitinib | 27% | 2.7% | +24.3 | wk 16 · n 511 | NCT03611751 Phase 3, secondary |
| etanercept | 27% | 7% | +20 | wk 12 · n 106 | NCT00078819 Phase 3, secondary |
| guselkumab | 70% | 2.4% | +67.6 | 100 mg · wk 16 · n 496 | NCT02207244 Phase 3, primary |
| icotrokinra | 46.5% | 2.3% | +44.2 | 100 mg QD · wk 16 · n 43 | NCT05223868 Phase 2, secondary |
| ixekizumab | 72.8% | 42.2% (Ustekinumab) | — | wk 12 · n 136 | NCT02561806 Phase 3, primary |
| mirikizumab | 64.3% | 6.5% | +57.8 | 250 mg Q4W · wk 16 · n 423 | NCT03482011 Phase 3, primary |
| picankibart | 80.3%a | 2% | +78.3 | wk 16 | NCT05645627 Phase 3, primary |
| risankizumab | 75.3% | 4.9% | +70.4 | wk 16 · n 304 | NCT02684370 Phase 3, primary |
| Roflumilast (Zoryve) | 22.4% | 2.3% | +20.1 | 0.3% cream · wk 8 · n 255 | NCT04211363 Phase 3, secondary |
| secukinumab | 79% | 57.3% (Ustekinumab) | — | 300 mg · wk 16 · n 334 | NCT02074982 Phase 3, primary |
| sonelokimab | 69.8% | 64.2% (Secukinumab) | — | 120 mg · wk 12 · n 53 | NCT03384745 Phase 2, secondary |
| Tapinarof | 18.8% | 1.6% | +17.2 | wk 12 · n 340 | NCT03956355 Phase 3, secondary |
| tildrakizumab | 38.6% | 2.4% | +36.2 | 100 mg · wk 16 · n 88 | NCT01225731 Phase 2, secondary |
| tofacitinib | 39.4% | 0.6% | +38.9 | 10 mg · wk 16 · n 360 | NCT01276639 Phase 3, secondary |
| ustekinumab | 54.1% | 5.4% | +48.7 | Half-Standard Dosage · wk 12 · n 37 | NCT01090427 Phase 3, secondary |
| zasocitinib | 46.2% | 0% | +46.2 | 30 mg · wk 12 · n 52 | NCT04999839 Phase 2, secondary |
Drugs checked with no result here: 24 not posted, 38 not reported, 14 trial running.
PASI 100 (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 18.4% | 2.7% (Methotrexate) | — | 0.8 mg/kg · wk 16 · n 38 | NCT01251614 Phase 3, secondary |
| bimekizumab | 61.7% | 48.9% (Secukinumab) | — | 320 mg Q4W · wk 16 · n 373 | NCT03536884 Phase 3, primary |
| deucravacitinib | 10.2% | 1.2% | +9 | wk 16 · n 511 | NCT03611751 Phase 3, secondary |
| guselkumab | 50% | 0% | +50 | wk 16 · n 62 | NCT02905331 Phase 3, secondary |
| icotrokinra | 23.3% | 0% | +23.3 | 100 mg QD · wk 16 · n 43 | NCT05223868 Phase 2, secondary |
| ixekizumab | 35% | 0% | +35 | 80 mg every 4 weeks · wk 12 · n 386 | NCT01646177 Phase 3, secondary |
| mirikizumab | 32.4% | 0.9% | +31.5 | 250 mg Q4W · wk 16 · n 423 | NCT03482011 Phase 3, secondary |
| risankizumab | 35.9% | 0% | +35.9 | wk 16 · n 304 | NCT02684370 Phase 3, secondary |
| secukinumab | 23.5% | 0% | +23.5 | wk 12 · n 51 | NCT02267135 Phase 3, secondary |
| sonelokimab | 37.7% | 28.3% (Secukinumab) | — | 120 mg · wk 12 · n 53 | NCT03384745 Phase 2, secondary |
| tildrakizumab | 14.8% | 0% | +14.8 | 100 mg · wk 16 · n 88 | NCT01225731 Phase 2, secondary |
| ustekinumab | 29.9% | 26.2% (Ustekinumab) | — | wk 16 · n 281 | NCT04607980 Phase 3, secondary |
| zasocitinib | 32.7% | 0% | +32.7 | 30 mg · wk 12 · n 52 | NCT04999839 Phase 2, secondary |
Drugs checked with no result here: 30 not posted, 40 not reported, 14 trial running.
sPGA 0/1 (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 60.5% | 40.5% (Methotrexate) | — | 0.8 mg/kg · wk 16 · n 38 | NCT01251614 Phase 3, primary |
| apremilast | 21.6% | 4.1% | +17.5 | 30 mg · wk 16 · n 297 | NCT03721172 Phase 3, primary |
| baricitinib | 34.8% | 14.7% | +20.1 | 10 mg · wk 12 · n 69 | NCT01490632 Phase 2, secondary |
| bimekizumab | 84.1% | 4.8% | +79.3 | 320 mg Q4W · wk 16 · n 321 | NCT03370133 Phase 3, primary |
| brepocitinib | 10.3% | 14.7% | −4.4 | 0.1% QD · wk 12 · n 29 | NCT03850483 Phase 2, secondary |
| certolizumab pegol | 57.9% | 4.2% | +53.7 | 400 mg Q2W · wk 16 · n 88 | NCT02326298 Phase 3, primary |
| desoximetasone | 38.7% | 34.1% | +4.6 | wk 4 · n 106 | NCT02932462 Phase 3, primary |
| deucravacitinib | 49.5% | 8.6% | +40.9 | wk 16 · n 511 | NCT03611751 Phase 3, primary |
| Envudeucitinib | 53.8% | 7.9% | +45.9 | 40mg QD · wk 12 · n 39 | NCT05600036 Phase 2, secondary |
| etanercept | 28.9% | 3.6% | +25.3 | 50 mg SC QW · wk 16 · n 83 | NCT01690299 Phase 3, secondary |
| guselkumab | 85.7% | 7.1% | +78.6 | 100 mg · wk 16 · n 42 | NCT01483599 Phase 2, primary |
| Halobetasol Propionate Lotion | 36.5% | 8.1% | +28.4 | wk 8 · n 143 | NCT02514577 Phase 3, primary |
| halobetasol propionate/tazarotene | 35.8% | 7.0% | +28.8 | wk 8 · n 135 | NCT02462070 Phase 3, primary |
| infliximab | 88.1% | 6.7% | +81.4 | wk 10 · n 84 | NCT01177800 Phase 3, secondary |
| ixekizumab | 75.4% | 6.7% | +68.7 | 80 mg every 4 weeks · wk 12 · n 386 | NCT01646177 Phase 3, primary |
| mirikizumab | 69.3% | 6.5% | +62.8 | 250 mg Q4W · wk 16 · n 423 | NCT03482011 Phase 3, primary |
| Piclidenoson | 6.4% | 3.5% | +2.9 | 2 mg · wk 16 · n 141 | NCT01265667 Phase 2/3, secondary |
| risankizumab | 87.8% | 7.8% | +80 | wk 16 · n 304 | NCT02684370 Phase 3, primary |
| secukinumab | 62.5% | 2.8% | +59.7 | 300mg · wk 12 · n 323 | NCT01358578 Phase 3, primary |
| Tapinarof | 35.4% | 6% | +29.4 | wk 12 · n 340 | NCT03956355 Phase 3, primary |
| tildrakizumab | 61.8% | 2.2% | +59.6 | 100 mg · wk 16 · n 89 | NCT01225731 Phase 2, secondary |
| tofacitinib | 68.2% | 14.9% | +53.2 | 10 mg BID · wk 12 · n 330 | NCT01241591 Phase 3, primary |
| ustekinumab | 67.6% | 5.4% | +62.2 | Half-Standard Dosage · wk 12 · n 37 | NCT01090427 Phase 3, primary |
| Voclosporin | 35%a | 6% | +29 | wk 12 | NCT00408187 Phase 3, primary |
| zasocitinib | 51.9% | 3.8% | +48.1 | 30 mg · wk 12 · n 52 | NCT04999839 Phase 2, secondary |
Drugs checked with no result here: 15 trial running, 22 not posted, 35 not reported.
DLQI, change (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | -4.8 | -4.2 | −0.6 | wk 16 · n 49 | NCT00735787 Phase 4, secondary |
| apremilast | -6.6 | -2.1 | −4.5 | 30 mg BID · wk 16 · n 556 | NCT01194219 Phase 3, secondary |
| baricitinib | -5.1 | -1.7 | −3.4 | 10 mg · wk 12 · n 68 | NCT01490632 Phase 2, secondary |
| Calcipotriene/Betamethasone Dipropionate Foam | 3 | 6 | −3 | wk 16 · n 14 | NCT03441789 Phase 4, secondary |
| certolizumab pegol | -10 | -3.8 | −6.2 | 400 mg Q2W · wk 16 · n 87 | NCT02326272 Phase 3, secondary |
| deucravacitinib | -10.2 | -2.9 | −7.3 | 12 mg QD · wk 12 · n 44 | NCT02931838 Phase 2, secondary |
| etanercept | -7.8 | -3.9 | −3.9 | 50 mg SC QW · wk 16 · n 80 | NCT01690299 Phase 3, secondary |
| guselkumab | -11.2 | -2.6 | −8.6 | 100 mg · wk 16 · n 495 | NCT02207244 Phase 3, secondary |
| infliximab | -8 | -1.5 | −6.5 | wk 10 · n 84 | NCT01177800 Phase 3, secondary |
| ixekizumab | -9.6 | -1.7 | −7.9 | 80 mg every 4 weeks · wk 12 · n 375 | NCT01646177 Phase 3, secondary |
| mirikizumab | -9.6 | -1.1 | −8.6 | 300 mg · wk 16 · n 49 | NCT02899988 Phase 2, secondary |
| risankizumab | -17 | -9.7 (Fumaderm) | — | wk 16 · n 59 | NCT03255382 Phase 3, secondary |
| Roflumilast (Zoryve) | -2.6 | -1.4 | −1.2 | 0.3% · wk 12 · n 58 | NCT03638258 Phase 2, secondary |
| secukinumab | -13.2 | -2.0 | −11.2 | 300 mg · wk 12 · n 41 | NCT03589885 Phase 3, secondary |
| tildrakizumab | -8.5 | 1 | −9.5 | 100 mg · wk 16 · n 88 | NCT01225731 Phase 2, secondary |
| tofacitinib | -8.9 | -1.9 | −7 | 10 mg · wk 16 · n 357 | NCT01276639 Phase 3, secondary |
| ustekinumab | -9 | -0.5 | −8.5 | 90 mg · wk 12 · n 402 | NCT00307437 Phase 3, secondary |
| zasocitinib | -8.9 | -4.9 | −4 | 30 mg · wk 12 · n 47 | NCT04999839 Phase 2, secondary |
Drugs checked with no result here: 16 trial running, 24 not posted, 39 not reported.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 97 approved or late-stage drugs with a featured trial in Psoriasis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.